Binod Dhakal, MD, on Superior PFS With Cilta-Cel Compared to SOC in Multiple Myeloma
The associate professor at Medical College of Wisconsin discussed new findings from the CARTITUDE-4 study.
“Looking at the CAR-T specific adverse events, for example, CRS, ICANS, and other side effects like cytopenias - all of them were lower in rates and severity than patients treated in later lines like the CARTITUDE-1 patient population. So, all this data suggests that cilta-cel can be a very effective option in patients with lenalidomide refractory multiple myeloma because it provides the superior PFS benefit and consistent PFS benefit across all risk subgroups, deep and durable responses and was found to be safer when used in early lines of treatment.”
Ciltacabtagene ciloleucel (cilta-cel; Carvykti; Janssen) chimeric antigen receptor (CAR) T-cell therapy yielded higher rates of progression-free survival (PFS) in patients with relapsed multiple myeloma after lenalidomide compared with standard of care (SOC) therapies. The new findings were revealed in updated data from the phase 3 CARTITUDE-4 study (NCT04181827) presented by Binod Dhakal, MD, associate professor, Medical College of Wisconsin, at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, held June 2-6, in Chicago, Illinois.1
CGTLive spoke with Dhakal to learn more about the new data from the CARTITUDE-4 study andhow the new findings should inform clinical decisions, care, and regulatory decisions. He stressed that cilta-cel should be considered as a new SOC for second-line treatment of MM. In keeping with the new findings, Legend Biotech just recently submitted a supplemental biologics license application for cilta-cel in the expanded indication.2
Click here for more coverage of ASCO 2023.
